EFPIA Commits To Decarbonize The Pharmaceutical Industry

The EFPIA or European Federation of Pharmaceutical Industries and Associations and its members have announced a commitment to science-based targets aimed at decarbonizing the pharmaceutical sector, emphasizing environmental sustainability. The organization stressed the importance of moving away from traditional practices and adopting innovative methods that minimize environmental impact.

Strategies for Enhancing Environmental Sustainability

EFPIA’s outlined targets include significant investments in renewable energy, promoting circularity, and collaborating with various stakeholders. The organization highlighted its dedication to taking concrete actions that reduce environmental impacts across the entire value chain, contributing to the development of resilient and sustainable health systems.

Key Focus Areas

Reduction In Carbon: EFPIA aims to decrease greenhouse gas emissions throughout its operations and value chains, urging suppliers to do the same. These targets will align with the Paris Agreement goals to limit global warming, and EFPIA will seek external verification for these targets.

Investing in Renewable Energy: The organization plans to enhance energy efficiency and transition to renewable energy sources for its facilities, investing in low-carbon clean technology solutions. EFPIA will also explore opportunities for on-site renewable energy generation and viable off-site renewable energy projects.

Circularity Advancement: EFPIA is committed to improving resource efficiency within its operations and value chain. This includes designing products with reduced environmental impacts, optimizing manufacturing processes and supply chains, managing waste effectively, and using sustainable packaging.

Collaboration with Stakeholders: EFPIA sees value in collaborating with other industry sectors, suppliers, and authorities to share best practices, research findings, and innovations in decarbonization efforts. The organization will support collaborative initiatives, such as industry-wide working groups, to foster innovation and collective problem-solving.

Addressing Pharmaceuticals in the Environment

EFPIA will continue to address concerns about the risks associated with pharmaceuticals in the environment- PiE. This involves engaging with stakeholders and the industry to improve processes, detect pharmaceuticals in the environment more effectively, and reduce the quantity of pharmaceuticals released from manufacturing plants worldwide.

In conclusion, EFPIA urged EU medicines regulators to prioritize flexibility and support for innovation in the redevelopment and supply of medicines, addressing climate, environmental, and sustainability targets.